Last reviewed · How we verify

Abiraterone acetate escalated dose — Competitive Intelligence Brief

Abiraterone acetate escalated dose (Abiraterone acetate escalated dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CYP17A1 inhibitor. Area: Oncology.

phase 2 CYP17A1 inhibitor CYP17A1 (17α-hydroxylase/17,20-lyase) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Abiraterone acetate escalated dose (Abiraterone acetate escalated dose) — Assistance Publique - Hôpitaux de Paris. Abiraterone acetate is a CYP17A1 inhibitor that blocks androgen synthesis, reducing testosterone production to treat androgen-dependent cancers.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Abiraterone acetate escalated dose TARGET Abiraterone acetate escalated dose Assistance Publique - Hôpitaux de Paris phase 2 CYP17A1 inhibitor CYP17A1 (17α-hydroxylase/17,20-lyase)
Fuzuloparib , Abiraterone acetate and Prednisone Fuzuloparib , Abiraterone acetate and Prednisone Jiangsu HengRui Medicine Co., Ltd. phase 3 PARP inhibitor (fuzuloparib) combined with CYP17A1 inhibitor (abiraterone acetate) and glucocorticoid (prednisone) PARP1/PARP2 (fuzuloparib); CYP17A1 (abiraterone acetate); glucocorticoid receptor (prednisone)
Abiraterone acetate and prednisone Abiraterone acetate and prednisone Janssen Research & Development, LLC phase 3 CYP17A1 inhibitor (androgen synthesis inhibitor) CYP17A1 (17α-hydroxylase/17,20-lyase)
Abiraterone Acetate (AA) Abiraterone Acetate (AA) Janssen Research & Development, LLC phase 3 CYP17A1 inhibitor CYP17A1 (17α-hydroxylase/17,20-lyase)
Abiraterone with Prednisone or Enzalutamide Abiraterone with Prednisone or Enzalutamide Curium US LLC phase 3 CYP17A1 inhibitor (abiraterone) + androgen receptor antagonist (enzalutamide) + glucocorticoid (prednisone) CYP17A1 (abiraterone); androgen receptor (enzalutamide); glucocorticoid receptor (prednisone)
Enzalutamide, Abiraterone Enzalutamide, Abiraterone Veru Inc. phase 3 Androgen receptor antagonist + CYP17A1 inhibitor combination Androgen receptor (AR) and CYP17A1
Abiraterone + Prednisolone/Prednisone Abiraterone + Prednisolone/Prednisone AstraZeneca phase 3 CYP17A1 inhibitor (androgen synthesis inhibitor) + glucocorticoid CYP17A1 (17α-hydroxylase/17,20-lyase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CYP17A1 inhibitor class)

  1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  2. Janssen Research & Development, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Abiraterone acetate escalated dose — Competitive Intelligence Brief. https://druglandscape.com/ci/abiraterone-acetate-escalated-dose. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: